Chest
Clinical InvestigationsCANCERSerum Levels of Vascular Endothelial Growth Factor Dependent on the Stage Progression of Lung Cancer
Section snippets
Patients
We prospectively investigated 49 consecutive lung cancerpatients who were admitted to the Department of Respiratory Medicine(National Minami-Kyushu Hospital) from 1995 to 1999, including 39 menand 10 women whose mean (± SD) age was 62.5 ± 12.3 years. Wedefinitely excluded the patients with clinical or conventionallaboratory evidence suggestive of intravascular coagulationabnormalities. We also excluded patients with diabetes mellitus, arteriosclerosis, and those receiving anticoagulant
Results
The serum levels of VEGF, and the plasma concentrations of TAT, Ddimer, and tPA/PAI complex were increased significantly according tothe stage of progression of disease (Table 1). There were no significant differences between the histologic patterns(Table 2).
There were significant positive correlations between TAT and VEGF(r = 0.322; p < 0.05), D dimer and VEGF(r = 0.42; p < 0.01), and tPA/PAI complex andVEGF (r = 0.365; p < 0.01). In patients with squamouscell carcinoma, there was a stronger
Discussion
According to stage progression, concentrations of TAT, D dimer, and tPA/PAI complex in plasma and concentrations of VEGF in serum weresignificantly increased. In lung cancer patients, Gabazza etal14 reported increases in levels of TAT, D dimer, and PICin patients with advanced stages of disease (ie, stages IIIband IV). Our results were almost the same as those of that report, except for the level of PIC, and we confirmed the activation of thecoagulation-fibrinolysis system in lung cancer
ACKNOWLEDGMENT
We thank especially Dr. Tetsuro Hamasaki and Dr. Joeji Wakimoto (Department of Respiratory Medicine, NationalMinami-Kyushu Hospital) for their support of this study.
References (19)
- et al.
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
Biochem Biophys Res Commun
(1991) Revisions in the international system for staging lung cancer
Chest
(1997)- et al.
Monoclonal antibodies to discrete regions in α2-plasmin inhibitor
Blood
(1987) - et al.
Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels
Thromb Res
(1990) - et al.
Evaluating prethrombotic state in lung cancer using molecular markers
Chest
(1993) - et al.
Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density
Anticancer Res
(1997) - et al.
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis
Anticancer Res
(1999) - et al.
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer
Int J Cancer
(1997) - et al.
Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions
Thorax
(1999)
Cited by (87)
Bevacizumab reduced auto-phosphorylation of VEGFR2 to protect HDM-induced asthma mice
2016, Biochemical and Biophysical Research CommunicationsCitation Excerpt :VEGF is a major transcriptional target for hypoxia-inducible factor (HIF)-1 and the VEGF/VEGF receptor (VEGFR) signaling pathway helps recovery from tissue damage and inflammation [3]. Studies also found VEGF expression in many lung diseases such as cancer, asthma, chronic obstructive pulmonary disease, lung injury, to name a few [4,5]. VEGF mediates cell permeability, cell migration, immune-surveillance, and angiogenesis in these pathological processes.
The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors
2016, Microvascular ResearchCitation Excerpt :As it was shown in the study by Dunst et al., tumor hypoxia is strongly associated with elevated VEGF serum levels (Dunst et al., 2001 Sep). The other possibility is that local VEGF production in the tumor is not sufficient to cause changes in its serum levels, but increased serum VEGF levels in the case of EOCs are due to metabolic changes which occur during advanced cancer disease (Matsuyama et al., 2000 Oct). Gadducci et al., showed, that increased serum VEGF are found only in stage III-IV EOCs, while in localized neoplasms (stage I-II according to FIGO) VEGF levels do not differ from controls (Gadducci et al., 1999 Mar-Apr).
Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma
2011, Microvascular ResearchVEGF and IL-18 in induced sputum of lung cancer patients
2011, CytokineBronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients
2011, Cancer LettersCitation Excerpt :Therefore, the main limitation of our study is the fact that platelet and leukocyte count of the patients was not taken into consideration in the analysis. Regarding the association between serum VEGF levels and intermediate prognostic markers, most studies report that VEGF levels are correlated to clinical stage [21,22]. In the present study, the only statistically significant associations were those of sVEGF, sVEGF/VEGFR2, wVEGF/VEGFR2 markers with T-classification.
ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells
2019, Oncology Reports